A closer look at “GSK's Cancer Comeback: Six Oncology Drugs in a Decade and Counting | Nova Global News”, exactly as the source publishes it. A decade after GSK exited oncology, the British drugmaker's return to cancer is paying off. The company, once a major player in the field, sold its oncology portfolio to Novartis in 2015 but has since rebuilt a pipeline that could soon yield its sixth cancer drug approval. GSK's Cancer Comeback: Six Oncology Drugs in a Decade and Counting
A decade after GSK exited oncology, the British drugmaker's return to cancer is paying off. This resurgence matters because oncology is now the largest and fastest-growing pharmaceutical market, and GSK's success shows how a big pharma can re-enter a competitive space through targeted acquisitions and internal R&D. Key recent milestones include the FDA approval of Jemperli for certain endometrial cancers and the acquisition of Sierra Oncology, which brought momelotinib for myelofibrosis. This listing links straight to the original page, where the content is available in full.